Health authorities have initiated a vaccination campaign aimed at protecting approximately one million teenagers and young adults from meningitis B. The programme focuses on individuals deemed to face the greatest immediate risk, particularly those preparing to enter university or residential further education settings.
Meningitis is an infection affecting the membranes surrounding the brain and spinal cord. While it can develop in any age group, it occurs most frequently in babies, young children, teenagers and young adults. The condition can result from either bacterial or viral causes, with bacterial forms being less common but considerably more severe than viral variants. Bacterial meningitis can progress to blood poisoning, sepsis, or brain involvement in its most serious form, known as invasive meningitis. Meningococcal group B, or MenB, accounts for the majority of severe meningococcal disease cases in the UK. Official data indicates 378 cases of invasive meningococcal disease occurred during 2024-2025.
Symptoms of meningitis develop rapidly and may include a non-blanching rash, sudden high fever, severe and worsening headache, neck stiffness, vomiting, diarrhoea, joint and muscle pain, light sensitivity, cold extremities, seizures, confusion, and extreme drowsiness. The infection spreads through close personal contact via respiratory droplets from coughs and sneezes, saliva exchange through kissing, or shared items such as vapes and drinks. Some individuals carry meningococcal bacteria in the nose or throat without becoming ill while remaining capable of transmitting infection to others.
Multiple vaccines offer protection against meningitis causes. The MenB vaccine protects against meningococcal group B bacteria and is recommended for infants beginning at eight weeks of age. The MenACWY vaccine provides coverage against four bacterial types and is offered to 14-year-olds. Additional vaccinations including pneumococcal, six-in-one, and MMRV vaccines provide indirect protection by preventing conditions that may lead to meningitis complications. The current vaccination programme will provide free MenB doses to Year 13 pupils and individuals under 25 beginning university or residential education this autumn. Anyone showing meningitis or sepsis symptoms should seek immediate emergency care, as early treatment can be life-saving.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI